Clinical trials: Small Cell Cancer
Non Small Cell Lung Cancer
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
- Trial name
- Cypress 2 (NCT03382912)
- Testing
- Pegilodecakin, Nivolumab
- Where
- 35 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
A study to evaluate the safety and tolerability of AMG 119 in adult subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate cell dose.
- Trial name
- NCT03392064
- Testing
- AMG 119
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
This randomized, Phase III, double-blind, placebo-controlled study will evaluate the safety and efficacy of MetMAb (onartuzumab) in combination with Tarceva (erlotinib) compared with treatment with Tarceva alone in patients with…
- Trial name
- NCT02031744
- Testing
- erlotinib [Tarceva], Onartuzumab [MetMAb]
- Where
- 8 sites in China
- Volunteers
- 530 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The risk of immunosuppression deters many patients from receiving fludarabine, while combination chemotherapy regimens are poorly tolerated by elderly or infirm chronic lymphocytic leukemia (CLL) patients.
- Trial name
- NCT01113632
- Testing
- Ofatumumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- SCRI Development Innovations, LLC
Carcinoma, Non-Small-Cell Lung
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
- Trial name
- NCT02182232
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Non-Small Cell Lung Cancer
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of…
- Trial name
- NCT01184287
- Testing
- Ranpirnase
- Where
- 6 sites in United States
- Sponsor
- Tamir Biotechnology, Inc.
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT07376499
- Testing
- Liposome Irinotecan, Platinum, Anlotinib
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Lymphoma, Neutropenia
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.
- Trial name
- NCT00005787
- Testing
- epoetin alfa, filgrastim, recombinant flt3 ligand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Gut Microbiota, NSCLC
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
- Conditions
- Gut Microbiota, NSCLC, Pembrolizumab, Chemotherapy
- Trial name
- NCT04333004
- Testing
- Pembrolizumab Combined With Chemotherapy
- Volunteers
- 40 people
- Sponsor
- Xiaorong Dong
Non-small Cell Lung Cancer
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
This is a Phase 1a/1b study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung…
- Trial name
- NCT05374538
- Testing
- VIC-1911, sotorasib
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Vitrac Therapeutics, LLC
Non-small Cell Lung Cancer
Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations
This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or METΔex14 detected on cfDNA.
- Trial name
- NCT05567055
- Testing
- Capmatinib
- Sponsor
- Timothy Burns, MD, PHD
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non Small Cell Lung Cancer
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
- Trial name
- NCT06082635
- Testing
- TGRX-326, Crizotinib
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase I1171N
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
The primary objective of this study is to evaluate the efficacy and safety of Ensartinib in advanced ALK-positive non-small cell lung cancer, and the mechanisms of population pharmacokinetics and resistance to Ensartinib.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase I1171N, Ensartinib
- Trial name
- NCT05498064
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation
This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving model based personalized chemoradiation.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT05010109
- Testing
- 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
NSCLC (Non-small Cell Lung Cancer), MRD
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
- Trial name
- CTONG 2508 (NCT07120698)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 115 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
- Trial name
- NCT06162221
- Testing
- RMC-6291, RMC-6236, Pembrolizumab
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 616 people
- Sponsor
- Revolution Medicines, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul